Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The association of HER-2/neu amplification with breast cancer recurrence
Autore:
Carr, JA; Havstad, S; Zarbo, RJ; Divine, G; Mackowiak, P; Velanovich, V;
Indirizzi:
Henry Ford Hosp, Dept Gen Surg K8, Josephine Ford Canc Ctr, Detroit, MI 48202 USA Henry Ford Hosp Detroit MI USA 48202 Ford Canc Ctr, Detroit, MI 48202 USA Henry Ford Hosp, Dept Surg & Biostat, Detroit, MI 48202 USA Henry Ford Hosp Detroit MI USA 48202 urg & Biostat, Detroit, MI 48202 USA Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA Henry Ford Hosp Detroit MI USA 48202 , Dept Pathol, Detroit, MI 48202 USA
Titolo Testata:
ARCHIVES OF SURGERY
fascicolo: 12, volume: 135, anno: 2000,
pagine: 1469 - 1474
SICI:
0004-0010(200012)135:12<1469:TAOHAW>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR-RECEPTOR; IN-SITU HYBRIDIZATION; PROTEIN OVEREXPRESSION; NEU ONCOGENE; IMMUNOHISTOCHEMICAL EVALUATION; PROGNOSTIC-SIGNIFICANCE; C-ERBB-2 AMPLIFICATION; TRASTUZUMAB HERCEPTIN; CELL-PROLIFERATION; GENE AMPLIFICATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Carr, JA Henry Ford Hosp, Dept Gen Surg K8, Josephine Ford Canc Ctr, 2799 W Grand Blvd, Detroit, MI 48202 USA Henry Ford Hosp 2799 W Grand Blvd Detroit MI USA 48202 48202 USA
Citazione:
J.A. Carr et al., "The association of HER-2/neu amplification with breast cancer recurrence", ARCH SURG, 135(12), 2000, pp. 1469-1474

Abstract

Hypothesis: Amplification of the HER-2/neu oncogene in 25% of breast cancers is associated with a shortened disease-free survival. Design: Retrospective analysis of a patient population referred to a tertiary care facility for HER-2/neu testing. The mean follow-up was 56 months. Setting: Large, urban, tertiary care hospital. Patients: From 1995 to 1999, a consecutive sample of 190 patients with breast cancer had tissue samples tested for overexpression of the cell surfaceoncoprotein by immunostaining (IM) or amplification of the HER-2/neu oncogene by fluorescence in situ hybridization or both. Forty-nine subjects wereexcluded because they had tissue samples tested at our institution but received their treatment elsewhere. All patients tested for HER-2/neu after diagnosis with breast cancer in 1999 (n=47) were excluded from analysis because of short follow-up time. One patient was excluded who had in situ ductalcarcinoma. The remaining 93 patients were analyzed. Results: Of 93 patients, 40 (43%) had gene amplification. Overall, patients with oncogene amplification had a shorter median disease-free interval (22 months) compared with controls (40 months) (P=.003). Analysis by the Cox regression model showed that the HER-2/neu status remained significantly associated with time to relapse even after adjusting for age and tumor grade (P.002; adjusted relative risk, 2.4; 95% confidence interval, 1.4-4.4). No association was found between gene amplification and tumor grade (P=.98), estrogen/progesterone receptor status (P=.29 and P=.43, respectively), or lymph node status (P=.98). Seventy-two patients (77%) eventually had disease recurrence, with 18 (25%) of these recurring locally. Conclusions: The HER-2/neu oncogene is an independent prognostic indicatorof a subset of breast cancers that are at high risk of early recurrence, regardless of tumor grade, estrogen/progesterone receptor status, and lymph node status. Patients amplifying the HER-2/neu oncogene have a shorter disease-free survival than patients without the oncogene.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 05:40:59